CDKN2A and metastatic melanoma: A NanoString miRNA array was applied to plasma-derived sEV samples of a cohort of 36 patients including sporadic metastatic melanoma patients, unaffected, and affected familial melanoma (CDKN2A/p16 gene alteration carriers) patients and healthy controls.